IL122296A0 - Quinolizinone type compounds - Google Patents
Quinolizinone type compoundsInfo
- Publication number
- IL122296A0 IL122296A0 IL12229696A IL12229696A IL122296A0 IL 122296 A0 IL122296 A0 IL 122296A0 IL 12229696 A IL12229696 A IL 12229696A IL 12229696 A IL12229696 A IL 12229696A IL 122296 A0 IL122296 A0 IL 122296A0
- Authority
- IL
- Israel
- Prior art keywords
- type compounds
- quinolizinone
- quinolizinone type
- compounds
- type
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/68—One oxygen atom attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46915995A | 1995-06-06 | 1995-06-06 | |
| US63811296A | 1996-05-29 | 1996-05-29 | |
| PCT/US1996/008991 WO1996039407A1 (en) | 1995-06-06 | 1996-06-05 | Quinolizinone type compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL122296A0 true IL122296A0 (en) | 1998-04-05 |
Family
ID=27042662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12229696A IL122296A0 (en) | 1995-06-06 | 1996-06-05 | Quinolizinone type compounds |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0871628A1 (en) |
| JP (1) | JPH11510478A (en) |
| KR (1) | KR19990022524A (en) |
| AU (1) | AU6153096A (en) |
| CA (1) | CA2222322A1 (en) |
| IL (1) | IL122296A0 (en) |
| MX (1) | MX9709416A (en) |
| WO (1) | WO1996039407A1 (en) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2259927A1 (en) | 1996-07-12 | 1998-01-22 | Leukosite, Inc. | Chemokine receptor antagonists and methods of use therefor |
| US5693813A (en) * | 1997-02-26 | 1997-12-02 | Abbott Laboratories | Process for preparation of 4H-4-oxo-quinolizine-3-carboxylic acid |
| KR100241673B1 (en) * | 1997-08-09 | 2000-03-02 | 김충섭 | Quinolizine Carboxylic acid Derivatives |
| RU2193558C2 (en) | 1997-09-15 | 2002-11-27 | Дзе Проктер Энд Гэмбл Компани | Derivatives of quinolone and pharmaceutical composition based on thereof |
| EP1115724A1 (en) | 1998-09-21 | 2001-07-18 | Shire Biochem Inc. | Quinolizinones as integrin inhibitors |
| DK1134219T3 (en) * | 1998-11-24 | 2005-10-17 | Daiichi Seiyaku Co | Cucloalkyl-substituted aminomethylpyrrolidine derivatives |
| KR100768034B1 (en) | 1999-03-17 | 2007-10-17 | 다이이찌 세이야꾸 가부시기가이샤 | Medicinal composition |
| AU1996301A (en) * | 1999-12-14 | 2001-06-25 | Neurosearch A/S | Novel heteroaryl-diazabicycloalkanes |
| DE19962470A1 (en) * | 1999-12-22 | 2001-07-12 | Schulz Hans Herrmann | Use of chemotherapy drugs |
| SE0100326D0 (en) * | 2001-02-02 | 2001-02-02 | Astrazeneca Ab | New compounds |
| US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US7232924B2 (en) | 2001-06-11 | 2007-06-19 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs |
| EP1437354B1 (en) * | 2001-09-28 | 2008-08-13 | Sato Pharmaceutical Co. Ltd. | 4-oxoquinolizine antimicrobials having 2-pyridone skeleton as partial structure |
| US6900224B2 (en) * | 2002-07-31 | 2005-05-31 | The Procter & Gamble Company | Antimicrobial quinolones, their compositions and uses |
| WO2005033108A1 (en) * | 2003-09-22 | 2005-04-14 | Janssen Pharmaceutica, N.V. | 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones |
| US7569599B2 (en) | 2003-12-12 | 2009-08-04 | Daiichi Pharmaceutical Co., Ltd. | Intermediates for the production of optically active cyclopropylamine derivatives and process for the production of the intermediates |
| US7977346B2 (en) | 2006-01-17 | 2011-07-12 | Guoqing Paul Chen | Spiro compounds and methods of use |
| WO2007110835A2 (en) | 2006-03-28 | 2007-10-04 | The Procter & Gamble Company | A coupling process for preparing quinolone intermediates |
| MY148393A (en) | 2006-03-28 | 2013-04-15 | Taigen Biotechnology Co Ltd | Malate salts, and polymorphs of (3s, 5s)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid |
| WO2008082009A2 (en) * | 2007-01-05 | 2008-07-10 | Daiichi Sankyo Company, Limited | Fused substituted aminopyrrolidine derivative |
| CN101622240B (en) * | 2007-01-05 | 2014-07-23 | 第一三共株式会社 | Fused Substituted Aminopyrrolidine Derivatives |
| US8124807B2 (en) | 2007-12-26 | 2012-02-28 | Msd K.K. | Sulfonyl-substituted 6-membered ring derivative |
| JP5433992B2 (en) * | 2008-06-26 | 2014-03-05 | Dic株式会社 | Method for producing fluorochromanol derivative |
| JP5433996B2 (en) * | 2008-07-10 | 2014-03-05 | Dic株式会社 | Method for producing fluorophenol derivative |
| EP2423211B1 (en) * | 2009-04-20 | 2014-04-16 | Kaneka Corporation | Processes for producing (1s,6s)- or (1r,6r)-cis-2,8-diazabicyclo[4.3.0]nonane and intermediate thereof |
| US8796297B2 (en) | 2009-06-30 | 2014-08-05 | Abbvie Inc. | 4-substituted-2-amino-pyrimidine derivatives |
| WO2011031745A1 (en) | 2009-09-09 | 2011-03-17 | Achaogen, Inc. | Antibacterial fluoroquinolone analogs |
| JP5487425B2 (en) * | 2009-09-11 | 2014-05-07 | 毅 野田 | Optically active 2-substituted-3-aminopiperidine derivatives and production method |
| ME02437B (en) | 2009-10-23 | 2016-09-20 | Janssen Pharmaceutica Nv | DISUBSTITUTED OCTAHY-DROPYRROLO [3,4-C] PYRROLE AS OREXIN RECEPTOR MODULATORS |
| EP2812004B1 (en) * | 2012-02-10 | 2018-06-27 | PTC Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| EP4249472A3 (en) | 2015-05-30 | 2023-12-13 | PTC Therapeutics, Inc. | Methods for modulating rna splicing |
| ES2879995T3 (en) | 2015-12-10 | 2021-11-23 | Ptc Therapeutics Inc | Methods for treating Huntington's disease |
| IL288321B2 (en) | 2016-03-10 | 2025-08-01 | Janssen Pharmaceutica Nv | Methods for treating depression using orexin-2 receptor antagonists |
| CN106543170B (en) * | 2016-10-27 | 2018-02-23 | 丹诺医药(苏州)有限公司 | The carboxylate of 8 chlorine, 1 cyclopropyl, 7 fluorine, 9 methyl, 4 oxygen, 4 hydrogen quinolizine 3 and its synthetic method |
| EA201991309A1 (en) | 2016-11-28 | 2019-11-29 | RNA SPLICING MODULATION METHODS | |
| EP4151627A1 (en) | 2017-06-05 | 2023-03-22 | PTC Therapeutics, Inc. | Compounds for treating huntington's disease |
| AU2018284853A1 (en) | 2017-06-14 | 2019-12-19 | Ptc Therapeutics, Inc. | Methods for modifying RNA splicing |
| MX2019015578A (en) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics Inc | Methods for treating huntington's disease. |
| CN111163838B (en) | 2017-06-28 | 2023-03-28 | Ptc医疗公司 | Methods for treating huntington's disease |
| MX2020009957A (en) | 2018-03-27 | 2021-01-15 | Ptc Therapeutics Inc | Compounds for treating huntington's disease. |
| EA202092899A1 (en) | 2018-06-27 | 2021-05-14 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | HETEROARYL COMPOUNDS FOR THE TREATMENT OF GENTINGTON'S DISEASE |
| SG11202012674PA (en) | 2018-06-27 | 2021-01-28 | Ptc Therapeutics Inc | Heterocyclic and heteroaryl compounds for treating huntington's disease |
| WO2020005882A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| WO2025143096A1 (en) * | 2023-12-29 | 2025-07-03 | キッセイ薬品工業株式会社 | Nitrogen-containing condensed ring compound |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2081891C (en) * | 1990-05-02 | 1999-03-16 | Daniel T. Chu | Quinolizinone type compounds |
| JPH09503783A (en) * | 1993-10-14 | 1997-04-15 | アボツト・ラボラトリーズ | Quinolidinone type compound |
-
1996
- 1996-06-05 AU AU61530/96A patent/AU6153096A/en not_active Abandoned
- 1996-06-05 CA CA002222322A patent/CA2222322A1/en not_active Abandoned
- 1996-06-05 KR KR1019970709005A patent/KR19990022524A/en not_active Ceased
- 1996-06-05 WO PCT/US1996/008991 patent/WO1996039407A1/en not_active Ceased
- 1996-06-05 EP EP96919103A patent/EP0871628A1/en not_active Withdrawn
- 1996-06-05 IL IL12229696A patent/IL122296A0/en unknown
- 1996-06-05 JP JP9501420A patent/JPH11510478A/en active Pending
-
1997
- 1997-12-02 MX MX9709416A patent/MX9709416A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0871628A1 (en) | 1998-10-21 |
| AU6153096A (en) | 1996-12-24 |
| JPH11510478A (en) | 1999-09-14 |
| CA2222322A1 (en) | 1996-12-12 |
| KR19990022524A (en) | 1999-03-25 |
| MX9709416A (en) | 1998-07-31 |
| WO1996039407A1 (en) | 1996-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL122296A0 (en) | Quinolizinone type compounds | |
| GB9508810D0 (en) | Compounds | |
| GB9500691D0 (en) | Compounds | |
| GB9504910D0 (en) | Compounds | |
| GB9504948D0 (en) | Compounds | |
| GB9512129D0 (en) | Compounds | |
| GB9520489D0 (en) | Compounds | |
| GB9602305D0 (en) | Compounds | |
| GB9502783D0 (en) | Compounds | |
| GB9504802D0 (en) | Compounds | |
| GB9508874D0 (en) | Compounds | |
| GB9518952D0 (en) | Compounds | |
| GB9520050D0 (en) | Compounds | |
| GB9520354D0 (en) | Compounds | |
| GB9520360D0 (en) | Compounds | |
| GB9520362D0 (en) | Compounds | |
| GB9520628D0 (en) | Compounds | |
| GB9521504D0 (en) | Compounds | |
| GB9522045D0 (en) | Compounds | |
| GB9500688D0 (en) | Compounds | |
| GB9501357D0 (en) | Compounds | |
| GB9501580D0 (en) | Compounds | |
| GB9501581D0 (en) | Compounds | |
| GB9506168D0 (en) | Compounds | |
| GB9502784D0 (en) | Compounds |